ReviewPharmaceutical research2002
A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.
Review in Pharmaceutical research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Importance of Computer-aided Drug Design in Modern Pharmaceutical Research.Current drug discovery technologies · 2025Review
- Structure-based molecular modeling in SAR analysis and lead optimization.Computational and structural biotechnology journal · 2021Review
- Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer.Medicinal research reviews · 2020Review
- Nuclear Receptor Metabolism of Bile Acids and Xenobiotics: A Coordinated Detoxification System with Impact on Health and Diseases.International journal of molecular sciences · 2018Review
- Discovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Small-molecule modulators of PXR and CAR.Biochimica et biophysica acta · 2016Review
- Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets.Journal of chemical information and modeling · 2015Article
- Targeting xenobiotic receptors PXR and CAR in human diseases.Drug discovery today · 2015Review
- Pregnane X receptor and drug-induced liver injury.Expert opinion on drug metabolism & toxicology · 2014Review
- Differential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse events.British journal of pharmacology · 2014Article
- Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).Molecular pharmaceutics · 2013Article
- Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective.Drug metabolism reviews · 2013Review
- Role of CAR and PXR in xenobiotic sensing and metabolism.Expert opinion on drug metabolism & toxicology · 2012Review
- Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.Journal of chemical information and modeling · 2012Review
- A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.BMC systems biology · 2011Article
- Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach.Current computer-aided drug design · 2011Review
- Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter.Journal of medicinal chemistry · 2010Article
- The structural basis of pregnane X receptor binding promiscuity.Biochemistry · 2009Article
- Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR.PLoS computational biology · 2009Article
- Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.Pharmaceutical research · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years discussion of nuclear hormone receptors, transporters, and drug-metabolizing enzymes has begun to take place as our knowledge of the overlapping ligand specificity of each of these proteins has deepened. This ligand specificity is potentially valuable information for influencing future drug design, as it is important to avoid certain enzymes or transporters in order to circumvent potential drug-drug interactions. Similarly, it is critical that the induction of these same proteins via nuclear hormone receptors is avoided, as this can result in further toxicities. Using a ligand-based approach in this review we describe new and previously published computational models for PXR, CAR, FXR, LXRalpha, and LXRbeta that may help in understanding the complexity of interactions between transporters and enzymes. The value of these types of models is that they may enable us to design molecules to selectively modulate pathways for therapeutic effect and in addition predict the potential for drug interactions more reliably. Simultaneously, we might learn which came first: the transporter, the enzyme, or the nuclear hormone receptor?
Indexed as
Identifiers
12523656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.